Contract Pharma Staff09.14.20
Sai Life Sciences, one of India's fastest growing contract development and manufacturing organizations (CDMOs), has added state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, MA.
Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities includes the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and biotech companies in the region, especially in projects exploring novel biology in oncology, neuroscience and rare diseases.
Over the past year, the lab has delivered a range of projects including genetic and pharmacological target validation studies, reagent validation, and developed a variety of assays for its clients, such as cellular target engagement assays and in vitro biomarker assessments.
Located in the heart of the Cambridge/Boston biotech ecosystem, Sai's 8,500 square feet lab in Kendall Square creates opportunities for local biotechs to have frequent face-to-face collaboration with Sai scientists, and to accelerate the pace of their externalized research by reducing cycle-times. The exploratory focus of the lab allows clients to externalize complex biology projects that necessitate more fluid experimental design with real-time decision making. Complementing the team in Cambridge is a larger biology team in India that works in tandem to present clients an optimal solution in terms of speed, cost and talent.
"We are committed to helping our clients successfully advance their internal discovery portfolios and are investing considerable resources to provide world-class service in the Boston area,” said Krishna Kanumuri, chief executive officer and managing directory, Sai Life Sciences. “These new capability additions are just the latest in our strategic growth plan with significant additional capabilities coming soon."
The Cambridge lab serves as a vital bridge, enabling seamless integration with rest of the company's service offerings across UK and India, spanning the drug discovery and development continuum including medicinal chemistry, DMPK and toxicology, process chemistry and analytical development, and commercial scale manufacturing.
Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities includes the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and biotech companies in the region, especially in projects exploring novel biology in oncology, neuroscience and rare diseases.
Over the past year, the lab has delivered a range of projects including genetic and pharmacological target validation studies, reagent validation, and developed a variety of assays for its clients, such as cellular target engagement assays and in vitro biomarker assessments.
Located in the heart of the Cambridge/Boston biotech ecosystem, Sai's 8,500 square feet lab in Kendall Square creates opportunities for local biotechs to have frequent face-to-face collaboration with Sai scientists, and to accelerate the pace of their externalized research by reducing cycle-times. The exploratory focus of the lab allows clients to externalize complex biology projects that necessitate more fluid experimental design with real-time decision making. Complementing the team in Cambridge is a larger biology team in India that works in tandem to present clients an optimal solution in terms of speed, cost and talent.
"We are committed to helping our clients successfully advance their internal discovery portfolios and are investing considerable resources to provide world-class service in the Boston area,” said Krishna Kanumuri, chief executive officer and managing directory, Sai Life Sciences. “These new capability additions are just the latest in our strategic growth plan with significant additional capabilities coming soon."
The Cambridge lab serves as a vital bridge, enabling seamless integration with rest of the company's service offerings across UK and India, spanning the drug discovery and development continuum including medicinal chemistry, DMPK and toxicology, process chemistry and analytical development, and commercial scale manufacturing.
